/PRNewswire/ Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(Nasdaq: PHAR) announces that the first patient has been enrolled.
Y-mAbs Therapeutics (YMAB) and EMA Reach Agreement on the Pediatric Investigation Plan for Naxitamab streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The glioblastoma multiforme market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such